Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of a combination
of levofloxacin, linezolid, cycloserine and pyrazinamide (or clofazimine if resistant to
pyrazinamide) treatments for 24 to 32 weeks (regimen consisted of clofazimine for 36~44
weeks) in subjects with multidrug-resistant tuberculosis (MDR-TB) compared to WHO
standardized shorter regimen of 36-44 weeks.
Phase:
N/A
Details
Lead Sponsor:
Huashan Hospital
Treatments:
Clofazimine Cycloserine Moxifloxacin Norgestimate, ethinyl estradiol drug combination Prothionamide Pyrazinamide